Is Regulation A Barrier to Innovation?
Is Regulation A Barrier to Innovation? Yes. Undeniably, unequivocally, yes. That is not a particularly satisfying answer, is it? The…
Publications
Read More
The status of current clinical practice in diagnosis of young onset dementia in England
Findings from the Angela Project Neuropsychiatry and behavioural neurology/assessment/measurement of neuropsychiatric/behavioural and psychological symptoms Background The presentation of dementia in…
Enhancing mental health research with better context for clinical concepts within EHRs
Our approach to accelerating research is grounded in the principle of data protection by design and default. The technologies and…
Why AI?
As we know, medical records can cover a long history of diseases (as Akrivia Health has found up to ninety…
What is Natural Language Processing (NLP)?
Natural Language Processing (NLP) is a form of Artificial Intelligence which processes language. Natural Language Processing (NLP) has existed for…
The acceleration of clinical trials through the optimisation of Akrivia Health’s platform
It is difficult to imagine the world of science without its laws dictating the need for clinical trials. Most probably…
The necessity of personalised data in precision medicine- A programme by Akrivia Health
It is probably true to say one of the most terrifying aspects of Alzheimer’s Disease (AD) is in its very…
The Burden associated with, and management of difficult-to-treat depression in patients under specialist psychiatric care in the United Kingdom
Background: Major depressive disorder (MDD) is common and often has sub-optimal response to treatment. Difficult-to-treat depression (DTD) is a new…
DCMS Data Reform Consultation Response
Introduction Akrivia Health works with a network of 16 mental healthcare organisations (the Akrivia Network) providing them with a service.…
MHRA Consultation Response
MHRA Consultation on Proposals for Legislative Changes to Clinical Trials Introduction Akrivia Health works with a network of 16 mental…
Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model
Abstract Background Donepezil, galantamine, rivastigmine and memantine are potentially effective interventions for cognitive impairment in dementia, but the use of…
Associated mortality risk of atypical antipsychotic medication in individuals with dementia
BACKGROUND Antipsychotic medications such as risperidone, olanzapine and aripiprazole are used to treat psychological and behavioural symptoms among dementia…
Validation of UK Biobank data for mental health outcomes: A pilot study using secondary care electronic health records
Highlights Linking UK Clinical Record Interactive Search (UK-CRIS) and UK Biobank. Comparison of diagnosis for 854 individuals present in both…
Telemachus
Overview A project between Oxford Health NHS Foundation Trust, Southern Health NHS Foundation Trust, the University of Oxford and Akrivia…
An efficient representation of chronological events in medical texts
Abstract In this work, we addressed the problem of capturing sequential information contained in longitudinal electronic health records (EHRs). Clinical…
Real-world effectiveness, its predictors and onset actions of cholinesterase inhibitors and memantine in dementia: retrospective health record study
Abstract Background The efficacy of acetylcholinesterase inhibitors and memantine in the symptomatic treatment of Alzheimer’s disease is well-established. Randomised trials…